GlassScriptPhysician profile
Lindsay Ward
NPI 1073901906
$2,908.77
in general payments reported to CMS, 2019-2025
19 companies · $280 in 2025
The $280 reported for 2025 was more than what 83% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $266 · 2022: $524 · 2023: $884 · 2024: $954 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $570.62 | 2023-2024 | Strensiq, Soliris |
| Sanofi Pasteur INC. | $326.62 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $311.58 | 2023-2024 | Xarelto |
| Novo Nordisk INC | $308.40 | 2021-2025 | Wegovy |
| Abbvie INC. | $248.18 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $150.77 | 2021 | |
| Sumitomo Pharma America, INC. | $118.22 | 2024 | |
| Vertos Medical, INC. | $117.21 | 2023 | Mild Device Kit |
| Coloplast Corp | $109.99 | 2024 | |
| Idorsia Pharmaceuticals US INC | $109.60 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.75 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $88.20 | 2024 | |
| Genzyme Corporation | $81.20 | 2024 | |
| Emd Serono, INC. | $75.79 | 2024 | |
| Boston Scientific Corporation | $59.19 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $50.52 | 2025 | |
| Genentech USA, INC. | $44.27 | 2024 | Xolair |
| Biogen, INC. | $24.88 | 2023 | |
| Lilly USA, LLC | $22.78 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.